Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0PETL)

Drug Name

SB-525334 Drug Info

Synonyms

356559-20-1; SB 525334; SB-525334; SB525334; 6-(2-(tert-Butyl)-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline; 6-[2-TERT-BUTYL-5-(6-METHYL-PYRIDIN-2-YL)-1H-IMIDAZOL-4-YL]-QUINOXALINE; CHEMBL401570; 6-[2-(1,1-DiMethylethyl)-5-(6-Methyl-2-pyridinyl)-1H-iMidazol-4-yl]quinoxaline; C21H21N5; 6-[2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline; 6-(2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline; MLS006011134; SCHEMBL373474; QCR-68; SCHEMBL10000768; CTK4H5088; CHEBI:91391; AOB5969

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 9967941
ChEBI ID: CHEBI:91391
CAS Number: CAS 356559-20-1
TTD Drug ID: DM0PETL

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting TGF-beta receptor type I (TGFBR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY2157299	DMP8HW1	Arteriosclerosis	BD40	Phase 2/3	[2]
TEW-7197	DM2LBC3	Myeloproliferative neoplasm	2A20	Phase 2	[3]
Metelimumab	DMENFD6	Scleroderma	4A42	Phase 1/2	[4]
TP-0184	DMJVZBC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
P-2745	DMJ3PNS	Chronic myelogenous leukaemia	2A20.0	Phase 1	[6]
LY3200882	DMQP6VB	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
PF-06952229	DMDQJEZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
SB-431542	DM0YOXQ	Pulmonary fibrosis	CB03.4	Preclinical	[9]
SM-16	DMHXJV2	Fibrosis	GA14-GC01	Terminated	[10]
LF-984	DMIYMS2	Fibrosis	GA14-GC01	Terminated	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
TGF-beta receptor type I (TGFBR1)	TTP4520	TGFR1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Synthesis and biological evaluation of 2-pyridyl-substituted pyrazoles and imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4228-4232 (2010).
2	Cardiac Safety of TGF-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. Cardiovasc Toxicol. 2015 Oct;15(4):309-23.
3	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4	Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004 Dec;3(12):1011-22.
5	Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
6	Novel potent inhibitor of Bcr-Abl mutated imatinib resistant chronic myeloid leukemia cell lines. Cancer Research. 06/2012; 72(8 Supplement):1822-1822.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Targeting the TGF pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31.
9	Pyrazolone based TGFbetaR1 kinase inhibitors. Bioorg Med Chem Lett. 2010 Jan 1;20(1):326-9.
10	TGF-beta type I receptor kinase inhibitor down-regulates rheumatoid synoviocytes and prevents the arthritis induced by type II collagen antibody. Int Immunol. 2007 Feb;19(2):117-26.
11	US patent application no. 2013,0028,978, Compositions and methods for wound treatment.